Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Glecaprevir/pibrentasvir in adults with chronic HCV genotype 1-6 infection and renal impairment has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Glecaprevir/pibrentasvir (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: COMPLETED | Results posted: 2019-03-04